

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

22-250s000

OFFICER/EMPLOYEE LIST

NDA 022250
Ampyra (dalfampridine) Extended Release Tablets

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Aisen, Daniel	Stockbridge, Norman L
Bastings, Eric P	Temple, Robert
Baugh, Denise V	Toscano, Amy
Best, Jeanine At	Touré, Hamet
Boehm, Gerard A	Toyer, Denise P
Bridges, Todd D	Wang, Yaning
Brown, Paul C	Watson, Sharon
Diaz, Jessica M	Yan, Xiaorong
El-Hage, Antoine	Yasuda, Sally U
Feibus, Karen B	Zhang, Joanne
Freed, Lois	
Heimann, Martha R	
Holquist, Carol A	
Houghtling, Richard	
Hughes, Alice	
Illoh, Kachikwu	
Jacobson-Kram, David	
Jin, Kun	
Karwoski, Claudia B	
Katz, Russell G	
Kelley, Laurie A	
Klein, Michael	
Krudys, Kevin M	
Lee, Joo Yeon	
Love, Lori A	
Mahayni, Houda	
Marroum, Patrick	
Mathis, Lisa L	
Mehta, Mehul U	
Men, Yuxin	
Moore, Christine M	
Ngo, Diem-Kieu H	
Nighswander, Robbin	
Parepally, Jagan Hohan R	
Purohit-Sheth, Tejashri S	
Reese, James H	
Reissig, Chad	
Seifried, Adele	
Soldatova, Lyudmila N	
Sood, Ramesh K	